Medicine and Dentistry
Human Immunodeficiency Virus
100%
Antiretroviral Therapy
49%
Infection
33%
Patient
30%
COVID-19
30%
Severe Acute Respiratory Syndrome Coronavirus 2
22%
Opportunistic Infection
20%
Retrovirus Infection
20%
Prevalence
18%
Therapeutic Procedure
17%
Woman
16%
Hepatitis C Virus
14%
Obesity
12%
Hepatitis C
11%
Hispanic
10%
Child
10%
Female
10%
Sequela
10%
Postcovid Syndrome
9%
Drug Resistance
8%
Hepatitis B Virus
8%
Hepatitis B
8%
Age
8%
Predictor
7%
Health
7%
Chemotherapeutic Agent
7%
Drug
7%
Dolutegravir
7%
Hepatitis Virus
6%
Mortality
6%
Combination Therapy
6%
Antiviral Therapy
6%
Follow up
6%
Placebo
6%
Race
6%
Hepatitis B Antigen
6%
Pregnant Adolescent
5%
Screening
5%
Adolescent
5%
Evaluation Study
5%
Hospital
5%
Nursing and Health Professions
Antiretroviral Therapy
50%
Patient
21%
Retrovirus Infection
18%
Opportunistic Infection
18%
Prevalence
17%
Infection
15%
Child
14%
Drug Resistance
10%
Prevention
10%
Hispanic
9%
Primary Medical Care
9%
Adult
9%
Health Care Personnel
9%
Procedures
8%
Time
8%
Human Immunodeficiency Virus Infection
8%
Drug
7%
Evaluation Study
7%
Hepatitis B
6%
Vaccination Policy
6%
Follow up
6%
Diseases
6%
Treatment Outcome
6%
Hospital
5%
Gender
5%
Hepatitis C
5%
Screening
5%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
49%
Opportunistic Infection
16%
Retrovirus Infection
16%
Remdesivir
14%
Drug Resistance
13%
Drug
13%
Infection
12%
Antiretrovirus Agent
10%
Prevalence
10%
Clinical Trial
8%
Diseases
7%
Baricitinib
7%
Integrase
7%
Virus
7%
Pharmacokinetics
6%
Placebo
6%
Fusion Inhibitor
5%
Human Immunodeficiency Virus 1
5%
Zidovudine
5%
Hepatitis C Virus
5%
Virus Hepatitis
5%
Hepatitis B
5%
